Autologous Anti-CD22 CAR-expressing T-cells SCRI-CAR22v2
autologous anti-cd22 car-expressing t-cells scri-car22v2
"A preparation of autologous human T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD22 CAR-expressing T-cells SCRI-CAR22v2 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces leading to lysis of CD22-expressing B-cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells."